3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA in rat brain: pharmacological manipulation

Eur J Pharmacol. 2000 Aug 25;402(3):215-22. doi: 10.1016/s0014-2999(00)00521-5.

Abstract

Using in situ hybridization and immunohistochemical techniques, we examined the expression pattern of egr-1 mRNA and Egr-1 protein in several brain regions following administration of 3, 4-methylenedioxymethamphetamine (MDMA). Furthermore, we also studied the role of N-methyl-D-aspartate (NMDA) receptor, dopamine D(1) receptor, 5-hydroxytryptamine (5-HT) transporter or 5-HT(2A) receptor in the induction of egr-1 mRNA by MDMA. Basal constitutive levels of egr-1 mRNA were detected in control rat brains. A single administration of MDMA (10 mg/kg) caused marked induction of egr-1 mRNA in the prefrontal cortex, striatum and hippocampal dentate gyrus. However, no changes in the egr-1 mRNA levels were detected in the CA1 region of hippocampus and occipital cortex after administration of MDMA (10 mg/kg). Furthermore, the expression of egr-1 mRNA in the prefrontal cortex, striatum and hippocampal dentate gyrus after administration of MDMA (10 mg/kg) was blocked significantly by pretreatment with NMDA receptor antagonist (5R, 10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]-cyclohepten-5, 10-imine ((+)-MK801; 1 mg/kg), dopamine D(1) receptor antagonist SCH 23390 (1 mg/kg) or 5-HT uptake inhibitor paroxetine (5 mg/kg), but not by 5-HT(2A) receptor antagonist SR46349B (5 mg/kg). However, high basal levels of Egr-1 immunoreactivity in the rat brain were not altered by administration of MDMA (10 mg/kg). These results suggest that MDMA alters the expression of egr-1 mRNA in several regions of rat brain, and that the expression of egr-1 mRNA by MDMA in the prefrontal cortex, striatum and hippocampal dentate gyrus appears to be mediated, at least in part, by NMDA receptor, dopamine D(1) receptor and 5-HT transporter.

MeSH terms

  • Animals
  • Benzazepines / pharmacology
  • Brain Chemistry / drug effects*
  • DNA-Binding Proteins / biosynthesis*
  • Dizocilpine Maleate / pharmacology
  • Dopamine Antagonists / pharmacology
  • Early Growth Response Protein 1
  • Excitatory Amino Acid Antagonists / pharmacology
  • Fluorobenzenes / pharmacology
  • Hallucinogens / pharmacology*
  • Immediate-Early Proteins*
  • Immunohistochemistry
  • In Situ Hybridization
  • Male
  • N-Methyl-3,4-methylenedioxyamphetamine / pharmacology*
  • Paroxetine / pharmacology
  • Phenols / pharmacology
  • RNA, Messenger / biosynthesis*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Dopamine D1 / antagonists & inhibitors
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Serotonin Antagonists / pharmacology
  • Transcription Factors / biosynthesis*

Substances

  • Benzazepines
  • DNA-Binding Proteins
  • Dopamine Antagonists
  • Early Growth Response Protein 1
  • Egr1 protein, rat
  • Excitatory Amino Acid Antagonists
  • Fluorobenzenes
  • Hallucinogens
  • Immediate-Early Proteins
  • Phenols
  • RNA, Messenger
  • Receptors, Dopamine D1
  • Receptors, N-Methyl-D-Aspartate
  • Serotonin Antagonists
  • Serotonin Uptake Inhibitors
  • Transcription Factors
  • SR 46349B
  • Paroxetine
  • Dizocilpine Maleate
  • N-Methyl-3,4-methylenedioxyamphetamine